The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
 
John H. Strickler
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Chengdu Kanghong Biotech; Genentech/Roche; Mereo Biopharma; Natera (Inst); OncoMed; Pfizer; Proteus Digital Health; Seagen (Inst)
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Curegenix (Inst); Exelixis (Inst); Gilead Sciences (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Nektar (Inst); OncoMed (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Seagen
 
Fang-Shu Ou
No Relationships to Disclose
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Bayer (Inst); Celgene (Inst); Immuneering; Imugene; Incyte (Inst); Ipsen (Inst); Lilly (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - ARMO BioSciences; AstraZeneca; Exelixis; Lilly; Merck (Inst); Sillajen
 
Christine Megerdichian Parseghian
No Relationships to Disclose
 
Andrea Cercek
Consulting or Advisory Role - Array Biopharma; Bayer; Proteus Digital Health
Research Funding - Abbvie; Rgenix (Inst); Seagen; Tesaro
 
Kimmie Ng
Consulting or Advisory Role - Seagen; X-Biotix Therapeutics
Research Funding - Genentech/Roche (Inst); Pharmavite (Inst); Revolution Medicines (Inst)
 
Federico Augusto Sanchez
Consulting or Advisory Role - Via Oncology
 
Sarah Bruggeman
No Relationships to Disclose
 
Joseph J. Larson
No Relationships to Disclose
 
Gene Grant Finley
Stock and Other Ownership Interests - Proteostasis Therapeutics
Speakers' Bureau - Bristol-Myers Squibb; Roche; Roche
Research Funding - AstraZeneca (Inst); BeyondSpring Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Joleen M. Hubbard
Consulting or Advisory Role - Bayer (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); Hutchison MediPharma (Inst); Merck (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Treos Bio (Inst)
 
Christina Wu
Consulting or Advisory Role - Array BioPHarma
Research Funding - Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Lycera (Inst); RAPT Therapeutics (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Symphogen (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - Array BioPharma
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; GlaxoSmithKline; Isofol Medical; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono
 
Scott Kopetz
Stock and Other Ownership Interests - Lutris; MolecularMatch; Navire
Consulting or Advisory Role - Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Biocartis; Boehringer Ingelheim; Boston Biomedical; Daiichi Sankyo; EMD Serono; EMD Serono; Genentech; HalioDx; Holy Stone Healthcare; Ipsen; Jacobio; Karyopharm Therapeutics; Lilly; Lutris; Merck; Natera; Navire; Novartis; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Roche; Symphogen
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Ryan Bruce Corcoran
Stock and Other Ownership Interests - Avidity Biosciences; C4 Therapeutics; Fount Therapeutics; Kinnate Biopharma; nRichDx; Revolution Medicines
Consulting or Advisory Role - Abbvie; Amgen; Array BioPharma; Asana Biosciences; Astex Pharmaceuticals; Avidity Nanomedicines; Bristol-Myers Squibb; C4 Therapeutics; Chugai Pharma; Elicio Therapeutics; FOGPharma; Fount Therapeutics; Genentech; Ipsen; Kinnate Biopharma; Loxo; Merrimack; N-of-One; Natera; Novartis; nRichDx; Revolution Medicines; Roche; Roivant; Shionogi; Shire; Spectrum Pharmaceuticals; Symphogen; Taiho Pharmaceutical; Warp Drive Bio; Zikani Therapeutics
Research Funding - Asana Biosciences; AstraZeneca; Lilly; Sanofi